Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2011

01-07-2011 | Original paper

Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype

Authors: Theodore M. Brasky, Matthew R. Bonner, Kirsten B. Moysich, Christine B. Ambrosone, Jing Nie, Meng Hua Tao, Stephen B. Edge, Bhaskar V. S. Kallakury, Catalin Marian, David S. Goerlitz, Maurizio Trevisan, Peter G. Shields, Jo L. Freudenheim

Published in: Cancer Causes & Control | Issue 7/2011

Login to get access

Abstract

Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of breast cancer, though findings have been inconsistent. This inconsistency may result from differences in etiology for breast tumors of different subtypes. We examined the association between NSAID use and breast cancer characterized by molecular subtypes in a population-based case–control study in Western New York. Cases (n = 1,170) were women with incident, primary, histologically confirmed breast cancer. Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (≥65 years). Participants answered questions regarding their use of aspirin and ibuprofen in the year prior to interview and their use of aspirin throughout their adult life. Logistic regression models estimated odds ratios (OR) and 95% confidence intervals (95% CI). Recent and lifetime aspirin use was associated with reduced risk, with no differences by subtype. Recent use of ibuprofen was significantly associated with increased risk of ER+/PR+(OR 1.33, 95% CI: 1.09–1.62), HER2− (OR 1.27, 95% CI: 1.05–1.53), and p53− breast cancers (OR 1.28, 95% CI: 1.04–1.57), as well as luminal A or B breast cancers. These findings support the hypothesis of heterogeneous etiologies of breast cancer subtypes and that aspirin and ibuprofen vary in their effects.
Appendix
Available only for authorised users
Literature
1.
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72(11):1605–1621PubMedCrossRef
2.
3.
Takkouche BR-MC, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1420–1423CrossRef
4.
Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192PubMedCrossRef
5.
Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13(5):669–678PubMedCrossRef
6.
Davies GLS (2003) Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 86(3–5):495–499PubMedCrossRef
7.
Brueggemeier RW, Diaz-Cruz ES (2006) Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol 31(1):13–26PubMed
8.
Brueggemeier RW, Diaz-Cruz ES, Li P-K, Sugimoto Y, Lin YC, Shapiro CL (2005) Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 95(1–5):129–136PubMedCrossRef
9.
Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96(16):9212–9217PubMedCrossRef
10.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
11.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423PubMedCrossRef
12.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374PubMedCrossRef
13.
Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151(7):703–714PubMed
14.
Hussain SP, Hollstein MH, Harris CC (2000) p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 919:79–85PubMedCrossRef
15.
Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113(7):1521–1526PubMedCrossRef
16.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef
17.
Gill J, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal Antiinflammatory Drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166(10):1150–1158PubMedCrossRef
18.
Kirsh V, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166(6):709–716PubMedCrossRef
19.
Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97(11):805–812PubMedCrossRef
20.
Ready A, Velicer, CM., McTiernan A, White E (2007) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. Published Online Aug 3, 2007
21.
Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk [see comment]. JAMA 291(20):2433–2440PubMedCrossRef
22.
Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the case-control surveillance study revisited. Am J Epidemiol 162(2):165–170PubMedCrossRef
23.
Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10(2):R38PubMedCrossRef
24.
Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121(1):211–215PubMedCrossRef
25.
Eliassen AH, Chen WY, Spriegelman D, Willet WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169(2):115–121PubMedCrossRef
26.
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. J Am Med Assoc 294(1):47–55CrossRef
27.
Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH et al (2010) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2010 Jul 29
28.
Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98(5):989–991PubMedCrossRef
29.
Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH et al (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21(9):1503–1512PubMedCrossRef
30.
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol 11(2):155–168
31.
Tennis M, Krishnan S, Bonner M, Ambrosone CB, Vena JE, Moysich K et al (2006) p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev 15(1):80–85PubMedCrossRef
32.
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang F-F et al (2009) Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control 20(3):361–368PubMedCrossRef
33.
Freedman AN, Michalek AM, Weiss HA, Zhang ZF, Marshall JR, Mettlin CJ et al (1998) Aspirin use and p53 expression in colorectal cancer. Cancer Detect Prev 22(3):213–218PubMedCrossRef
34.
Wacholder S, Hartge P, Lubin JH, Dosemeci M (1995) Non-differential misclassification and bias towards the null: a clarification [comment]. Occup Environ Med 52(8):557–558PubMedCrossRef
35.
Singh-Ranger G, Mokbel K (2002) The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 28(7):729–737PubMed
36.
Harris RE, Beebe-Donk J, Doss H, Burr-Doss D (2005) Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 13:559–583PubMed
37.
McTiernan A, Wu L, Barnabei VM, Chen C, Hendrix S, Modugno F et al (2008) Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(2):217–231PubMedCrossRef
38.
Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW et al (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(3):680–687PubMedCrossRef
39.
Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 19(4):1033–1041PubMedCrossRef
40.
Singh-Ranger G, Kirkpatrick KL, Clark GM, Mokbel K (2003) Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 19(2):131–134PubMedCrossRef
41.
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90(2):423–429PubMedCrossRef
42.
McCarthy K, Bustin SA, Ogunkolade B, Khalaf S, Laban CA, McVittie CJ et al (2006) Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer. Eur J Surg Oncol 32(7):707–709PubMedCrossRef
43.
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed
44.
Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S et al (2005) Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 72(5):241–249PubMedCrossRef
45.
Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH et al (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66(10):5504–5511PubMedCrossRef
46.
Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277(21):18649–18657PubMedCrossRef
47.
Benoit V, Relic B, Leval Xd, Chariot A, Merville M-P, Bours V (2004) Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 23(8):1631–1635PubMedCrossRef
48.
Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A et al (2006) Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 25(42):5708–5718PubMedCrossRef
49.
Han JA, Kim J-I, Ongusaha PP, Hwang DH, Ballou LR, Mahale A et al (2002) P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 21(21):5635–5644PubMedCrossRef
50.
Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH et al (2006) Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 15(3):390–398PubMedCrossRef
Metadata
Title
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype
Authors
Theodore M. Brasky
Matthew R. Bonner
Kirsten B. Moysich
Christine B. Ambrosone
Jing Nie
Meng Hua Tao
Stephen B. Edge
Bhaskar V. S. Kallakury
Catalin Marian
David S. Goerlitz
Maurizio Trevisan
Peter G. Shields
Jo L. Freudenheim
Publication date
01-07-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 7/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9769-9

Other articles of this Issue 7/2011

Cancer Causes & Control 7/2011 Go to the issue

Original paper

Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case–control study

Original paper

Alcohol and tobacco, and the risk of cancers of the upper aerodigestive tract in Latin America: a case–control study

Original paper

Green tea and coffee consumption and its association with thyroid cancer risk: a population-based cohort study in Japan

Original paper

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

Original paper

Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis

Brief report

Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits